Avicenna.AI’s advanced AI detection tools are now available via the CARPL platform.
Marseille, FRANCE – November 22, 2022 – Medical imaging AI specialist Avicenna.AI today
announced a distribution agreement with CARPL.ai, a technology platform that enables service provider-oriented testing, validation and deployment of AI applications to healthcare providers.
As the number of AI applications coming into the clinical realm increases, it can be challenging for healthcare providers to access, assess and then integrate these solutions into their clinical workflows. CARPL bridges this gap by acting as an intermediary platform for the development, testing, distribution and deployment of AI applications.
The CARPL platform now includes Avicenna.AI’s range of CINA solutions for neurovascular and thoraco-abdominal pathologies, which use deep learning to identify, detect and quantify life-threatening pathologies from CT medical images. The FDA-cleared and CE-Marked tools are seamlessly integrated within the clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists.
Using a combination of deep learning and machine learning technologies, the CINA solutions
automatically detect and prioritize cases within seconds, and assess them for severity, seamlessly alerting radiologists within their existing systems and workflow.
“CARPL.ai specializes in driving the adoption of radiology AI solutions into clinical workflows and improves patient outcomes, by enabling and empowering healthcare service providers to discover, explore, and validate cutting-edge AI and then deploy it in their environment with confidence,” said Dr. Vidur Mahajan, Chief Executive Officer of CARPL.ai. “When it comes to stroke care and other life-threatening conditions, we are delighted to now be able to offer Avicenna’s portfolio as a comprehensive solution to our customers.”
“We’re excited to partner with a leading platform like CARPL, which has a strong presence in key new markets for us, including Australia, Brazil and India,” said Cyril Di Grandi, co-founder, and CEO of Avicenna.AI. “They are also deployed in many large hospital environments, which is exactly what our solutions are designed for – delivering faster detection of critical conditions, improving radiology efficiency and supporting better patient outcomes.”
Avicenna.AI will be attending RSNA 2022, November 27 – 30. To book a meeting, email
Founded in 2018, Avicenna.AI develops medical imaging AI solutions for highly prevalent pathologies. The company uses artificial intelligence and deep learning to optimize many of a radiologist’s manual tasks. Its CINA products leverage deep learning algorithms to identify acute abnormalities and support emergency room triage. Avicenna.AI is co-founded by Cyril Di Grandi, who previously co-founded and successfully sold Olea Medical, and Dr. Peter Chang, a radiologist and internationally recognized expert in AI and deep learning.
CARPL is an end-to-end technology platform for the development, testing, distribution and
deployment of medical imaging AI applications in clinical workflows. Used by some of the world’s top AI researchers and health systems, it connects AI applications and healthcare providers helping improve access, affordability, and quality of medical care.